CYTK - Cytokinetics, Incorporated Latest News | Finranks

11.05.2026

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten.

08.05.2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,478,873 additional shares, at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $805 million. All of the shares of common stock in the offering were sold by Cytokinetics.

07.05.2026

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

06.05.2026

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

06.05.2026

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

05.05.2026

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago.

05.05.2026

Cytokinetics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its common stock in an underwritten public offering.

Videos

28.10.2025

Positive

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
CYTK	Raymond James	Market Perform	undefined >> undefined	July 30th 2025

Press releases

11.05.2026

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

08.05.2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

07.05.2026

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

05.05.2026

Cytokinetics, Incorporated (CYTK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cytokinetics, Incorporated (CYTK)

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Videos

Upgrades / Downgrades

Press releases

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Videos

Upgrades / Downgrades

Press releases

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Search stocks

Cytokinetics, Incorporated (CYTK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cytokinetics, Incorporated (CYTK)

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Videos

Upgrades / Downgrades

Press releases

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Announces Proposed Public Offering of Common Stock

Videos

Upgrades / Downgrades

Press releases

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Announces Proposed Public Offering of Common Stock